XT
RLMD icon

XTX Topco’s Relmada Therapeutics RLMD Stock Holding History

XTX Topco’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$234K Sell
33,606
-7,687
-19% -$36.4K ﹤0.01% 2724
2025
Q4 		$199K Buy
+41,293
New +$138K 0.01% 2404
2025
Q3 		– Sell
-46,039
Closed -$27.6K – 3157
2025
Q2 		$27.6K Buy
+46,039
New +$23.6K ﹤0.01% 2121
2024
Q1 		– Sell
-22,009
Closed -$91.1K – 2242
2023
Q4 		$91.1K Buy
+22,009
New +$65.2K 0.02% 1137
2023
Q3 		– Sell
-10,767
Closed -$26.5K – 1941
2023
Q2 		$26.5K Sell
10,767
-75,500
-88% -$209K ﹤0.01% 1299
2023
Q1 		$195K Sell
86,267
-43,120
-33% -$149K 0.04% 969
2022
Q4 		$452K Buy
+129,387
New +$1.14M 0.1% 350

Other funds holding RLMD

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $273M AUM
SSC
Spruce Street Capital New York $416M AUM
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

XTX Topco's RLMD Position: Q1 2026 in Review

XTX Topco reduced its Relmada Therapeutics (RLMD) stake by 19% in Q1 2026, selling an estimated $36.4K and leaving 33,606 shares worth $234K. The position accounts for ﹤0.01% of the portfolio, ranked #2724.

XTX Topco first reported a position in RLMD in Q4 2022 and has held it in 7 quarters since. The position peaked at $452K in Q4 2022. 103 funds tracked by Wall St. Rank hold RLMD as of Q1 2026.

  • XTX Topco held 33,606 shares of Relmada Therapeutics worth $234K as of Q1 2026.
  • XTX Topco sold 7,687 Relmada Therapeutics shares in Q1 2026, an estimated $36.4K.
  • Relmada Therapeutics made up ﹤0.01% of XTX Topco's portfolio in Q1 2026, its #2724 holding.
  • XTX Topco first reported a position in Relmada Therapeutics in Q4 2022 and has held it in 7 quarters since.
  • XTX Topco's Relmada Therapeutics position peaked at $452K in Q4 2022.
  • 103 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q1 2026.

Based on XTX Topco's 13F filing for Q1 2026, filed 15 May 2026.